The pharmacokinetics of cefoperazone, a new semisynthetic cephalosporin, were studied in 34 patients with neoplastic disease. This compound was administered in a variety of doses and schedules without observable toxicity in any patient. The mean peak serum concentration after a 15-min intravenous infusion of 2 g was 264 Ag/ml after the first dose; the serum half-life was 2.1 h. There was no significant change in half-life or serum concentrations after 4 or 7 days of therapy. The mean peak serum concentration after infusion of 1 g over 15 min was 133 ,ug/ml, with a mean of 10.7 ug/ml at 6 h. The serum half-life was 2 h. The mean peak serum concentration after infusion of 1 g over 0.5 h was 101 ,tg/ml.
When 8 g was subsequently administered daily by a continuous infusion schedule, levels were maintained at 80 ,ug/ml. When the dose was increased to 16 g daily, serum concentrations were maintained at an average of 153 ,g/ml. Only 37% of cefoperazone was recovered in the urine in a 12-h period after the initial dose, suggesting the importance of other mechanisms of excretion; however, serum concentrations in one patient with renal insufficiency were significantly higher than serum concentrations in patients with normal renal function.
Cefoperazone, a new semisynthetic cephalosporin derivative, has a broader spectrum of activity than most cephalosporins in current use and is highly resistant to ,B-lactamases produced by many gram-negative organisms (12, 14) . Its activity against indole-positive Proteus spp. and Pseudomonas aeruginosa is of particular interest. It has been reported to have greater activity against Pseudomonas spp. than moxalactam and cefotaxime (6, 10) . In studies conducted at our institution, it inhibited growth of the majority of all gram-negative organisms at concentrations of 3.12 jig/ml. Pseudomonas spp. and Enterobacter spp. were exceptions: concentrations of 12.5 itg/ml inhibited 75% of isolates of those organisms. The in vitro activity of cefoperazone against gram-positive aerobic organisms and anaerobes compares favorably with the activities of other cephalosporins (2, 8, 12) , with the exception of certain Bacteroides spp., which are significantly more susceptible to cefoxitin. Toxic reactions to this drug in animals and humans have been minor. Because of its broad spectrum of activity against gram-negative bacilli, cefoperazone is of great interest in the treatment of immunosuppressed cancer patients in whom these organisms cause the majority of infections (7) .
Studies of the pharmacokinetic properties of cefoperazone, carried out in a group of patients with malignant diseases, are recorded in this report. All patients were hospitalized for treatment of their primary disease or complications; hence, they represent a population in which the drug might be used therapeutically.
MATERIALS AND METHODS
Studies were carried out in 17 female and 17 mae patients ranging in age from 16 concentrations were 39.3, 8.1, and 3.5 ug/ml, respectively. The highest concentration in any patient was 330 ,ug/ml after 15 min, and the lowest concentration at that time was 200 Ag/ ml. After 12 h, the highest concentration was 14.8 Ag/ml, and the, lowest was 0.6 Ag/ml. The mean serum concentration before admninistration of the drug was 3.6 ,Lg/ml on day 3 or 4 and 4.5 ,ug/ml on day 7 or 8. The other concentrations were not different from those measured on day 1. Ten patients were given 1 g of cefoperazone every 6 h ( Table 2 ). In this group, the mean peak concentration on day 1 was 132.7 ,ug/ml at 15 min, and the concentrations at 30 min, 4 h, and 6 h were 95.0, 20.7, and 10.7 ,Lg/ml, respectively. The ti/2p for this group was 2.0 h. The concentration before administration of the drug on day 3 or 4 was 12.0 ,ug/ml and on day 7 or 8 was 11.5 ,ug/ml. No significant difference in the other concentrations was noted on day 3 or 4 and day 7 or 8 when compared with those measured on day 1.
In eight patients who received the continuous infusion schedule, the peak serum concentration at 30 min was 101.3 ug/ml (Fig. 1) . After the on June 29, 2017 by guest http://aac.asm.org/ Downloaded from loading dose, the serum concentrations remained fairly constant for the remainder of the study at 77 to 100 ,ug/ml, with minor day-to-day fluctuations. Slightly higher concentrations were noted during the last 3 days of the study, but these differences were not statistically significant.
In nine patients, the dose was increased to 16 g daily on day 4 (Fig. 2) . The serum concentration increased after 16 h to 153 jug/ml in these patients. No accumulation was seen during the 3 days of administration at this higher dose. After a total of 7 days of infusion of cefoperazone, six of these patients had serial blood samples drawn starting when drug administration was discontinued to determine the half-life after maintenance of constant blood levels for a prolonged time. Those data are plotted with the data from the 6-and 12-h intermittent studies (Fig. 3) of patients on the 6-and 12-h schedules.
One patient with moderate renal insufficiency (creatinine level of 2.2 mg/dl) was given cefoperazone on a continuous schedule at 8 g daily (Fig. 4) . The peak serum concentration occurred 1 h after starting the loading dose (1 g over 0.5 h). The serum concentrations rose slowly over the 7 subsequent days, reaching a maximum on the last day of 230 jig/ml, more than twice the 400 300 Patients given cefoperazone on the 12-h schedule had urine samples collected over the first 12 h of study (Table 3) . Twenty-three percent of the administered dose of cefoperazone was recovered in the urine after 3 h, 33% was recovered up to 6 h, and 37% was recovered up to 12 h after an initial bolus dose of 2 g was given. Patients given continuous infusion had urine collected for 6 h on day 3 or 4 of the study. Twenty-six percent of the dose was recovered over the 6-h period.
The calculated pharmacokinetic results for cefoperazone at doses of 1 and 2 g are summarized in Table 4 . No significant toxicities were encountered in any of the 34 patients studied. Two patients reported diarrhea which was minor and which resolved upon discontinuation of the drug. Minimal bactericidal concentrations required to kill the majority of gram-negative organisms with cefoperazone are often two to four dilutions higher than the minimal inhibitory concentration (6) . To attain minimal bactericidal concentrations for organisms marginally susceptible to this drug, serum concentrations in excess of 100 ,ug/ml might be required. Administration of cefoperazone by continuous infusion produced serum levels in this range without apparent toxicity. The administration of this drug in a patient with renal insufficiency resulted in significantly higher concentrations than in patients with normal renal function in spite of the relatively low renal excretion of this drug. In this regard, cefoperazone appears to behave like cefazolin, in that the half-life is significantly prolonged in patients with moderate renal failure (creatinine clearance, 33 to 48 ml/min) (1).
DISCUSSION
The eventual role to be played by this drug in the overall management of infections in patients with neoplastic diseases remains to be seen. In vitro susceptibility of bacterial isolates from such patients and data concerning attainable serum concentrations in these patients suggest that administration of cefoperazone should be effective therapy for most infections encountered in these patients.
